Skip to main content

Table 1 Overview of basic characteristics of CVOTs terminated in 2015 and published in 2016

From: Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group

  Study status Drug Drug class Intervention Primary outcome N Follow-up (years) Start and estimated end date Clinicaltrials.gov ID
EMPA-REG Completed Empagliflozin SGLT-2 inhibitor Empagliflozin 10 mg versus empagliflozin 25 mg versus placebo CV death, MI, or stroke 7000 3.1 07.2010 to 04.2015 NCT01131676
LEADER Completed Liraglutide GLP-1 inhibitor Liraglutide versus placebo CV death, MI, or stroke 9340 3.8 08.2010 to 12.2015 NCT01179048
SUSTAIN-6 Completed Semaglutide GLP-1 inhibitor Semaglutide 0.5 mg versus semaglutide 1.0 mg versus placebo CV death, MI, or stroke 3299 1.99 02.2013 to 01.2016 NCT01720446